Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 8/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | CSF1R | P07333 | 3/20 | 0.84 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.84 |
| ▸ | PLK4 | O00444 | 2/20 | 0.84 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.84 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.84 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.84 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.84 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.84 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.84 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.84 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.84 |
| ▸ | INSR | P06213 | 2/20 | 0.84 |
| ▸ | LCK | P06239 | 2/20 | 0.84 |
| ▸ | FYN | P06241 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29856494 | 1.00 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL905668 | 1.00 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL29856539 | 0.95 | PRKAA1 (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL27275642 | 0.95 | PRKAA1 (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL15459734 | 0.92 | KDR (0.85) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| Sunitinib SCHEMBL25343938 | 0.91 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| Sunitinib SCHEMBL20805212 | 0.91 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| Sunitinib SCHEMBL30314241 | 0.91 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| Sunitinib SCHEMBL25343935 | 0.91 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| Sunitinib SCHEMBL8082 | 0.91 | KDR (1.00) | KDRPDGFRBPRKAA1PRKAA2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| EP-1765313-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002422-A9 | COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006002422-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | KDR 2584/4885PDGFRB 3406/4885PRKAA1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.